Abstract:The treatment of locally advanced esophageal carcinoma remains a great challenge. For patients who are not surgical candidates, the majority of them are managed primarily with chemoradiation. However, radiation dose has been controversial. A prospective phase II study (ChiCTR-OIC-17010485) was conducted to determine the tolerance and efficacy of high dose intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for inoperable locally advanced esophageal squamous cell carcinoma (SCC). Eligibility criteria were: (1) histologically or cytologically proven esophageal SCC; (2) age 18-80 years; (3) Karnofsky performance status (KPS) ≥70; (4) clinical stages of I-IVA (AJCC,2002) with disease unresectable or inoperable, or the refusal of surgery; (5) no chemotherapy or surgery before enrollment; (6) normal liver, kidney and bone marrow functions; (7) no previous cancer history. Patients underwent IMRT for thoracic esophageal SCC. PTV1 composed of a 1.2-1.5 cm margin lateral around GTV and 3.0 cm margin superior/inferior of GTV. PTV2 encompassed GTV with a margin of 0.5-0.7 cm. The dose for PTV1 was 50 Gy in 2 Gy daily fractions; subsequently, PTV2 received a boost of 16 Gy in 2 Gy daily fractions to a total dose of 66 Gy. The concurrent chemotherapy regiments were fluorouracil (600mg/m2,d1-3) combined ciplatin (25mg/m2, d1-3) with 2 cycles and consolidate chemotherapy 2 cycles. A total of 86 patients were included with a median age of 64 years. The number of patients with stage I, II,III,IVA were 1,20,37 and 28, respectively. The median follow-up time was 19 months. None experienced CTCAE grade 4. The hematological toxicity with CTCAE grade 1,2,3 was 19%, 48.1% and 22.8%. The acute radiation esophagitis developed in 70% of patients with RTOG grades 1-2,and in 3.8% with grade 3. RTOG 1-2 radiation pneumonitis occurred in 20.8% of patients and in 1.3% with grade III. The rate of two-year overall survival, progression-free survival, distant metastasis and local control were 62.3%,35.5%,52.8% and 48.9%, respectively. Patients with inoperable locally advanced esophageal cancer received high dose of 66Gy IMRT with concurrent chemotherapy had a good tolerance and two-year overall survival was 62.3%. We warrant further studies evaluating the effectiveness of this approach compared with standard dose of 50.4Gy and chemotherapy.

[Phase II Clinical Trial of Sodium Glyci-Didazole (Cm-Na) Combined with Concurrent Radiochemotherapy for Advanced Esophageal Carcinoma].

Effect of the combination of Elemene and concurrent chemoradiation with cisplatin followed by consolidation chemotherapy with cisplatin and fluorouracil for locally advanced esophageal cancer

A Phase III Multicenter Trial of Radiosensitizing Effect and Safety of Sodium Glycididazole in Thoracic Esophegeal Squamous Carcinoma

[Phase II Clinical Trial of Concurrent Chemoradiotherapy (cisplatin Plus 5-Fluorouracil) for Esophageal Cancer].

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Phase 2 Study of Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable Locally Advanced Esophageal Squamous Cell Carcinoma

Cetuximab Combined with Concurrent Chemoradiotheray in Chinese Patients with Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter Phase II Trial.

A Phase II Study of Concurrent Chemoradiotherapy with Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma.

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

A Phase II Study of Neoadjuvant Chemoradiotherapy with Docetaxel, Cisplatin and 5-FU Followed by Surgical Resection in the Treatment of Locally Advanced Esophagogastric Junction Cancer and Locally Advanced Esophageal Cancer

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Phase II Trial of Irinotecan and Cisplatin Combination As First-Line Chemotherapy in Patients with Advanced Esophageal Squamous-Cell Carcinoma: an Interim Report.

A double blind radomized stage Ⅱ clinical trial of radiosensitizer Metronidazole-amino-acidum-natrium(CMNa) with concurrent chemoradiotherapy for thorax segment esophageal carcinoma

Clinical Study of Concurrent Chemoradiotherapy or Radiotherapy Alone for Esophageal Cancer Patients with Positive Lymph Node Metastasis.

Cetuximab, Paclitaxel, Cisplatin and Concurrent Radiation in Chinese Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: an Open-Label, Multicenter, Phase II Study.

Nimotuzumab Combined with Radiotherapy on Esophageal Cancer: Preliminary Study of a Phase II Clinical Trial.

Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail

Phase II Multicenter Trial: First-Line Immunochemotherapy with or Without Radiotherapy in Metastatic Esophageal Squamous Cell Cancer (SCR-ESCC-01)

A Phase III Clinical Trial of Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus.

Phase II Study of Definitive Chemoradiation Therapy Using S-1 for Esophageal Squamous Cell Carcinoma Patients --- the ESO-Shanghai 7 Trial Protocol

Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II–III Esophageal Squamous Cell Carcinoma